Sirtuins can promote deacetylation of a wide range of substrates in diverse cellular compartments to regulate many cellular processes 1, 2 ; recently, Narayan et al. 3 reported that SIRT2 was required for necroptosis on the basis of their findings that SIRT2 inhibition, knockdown or knockout prevented necroptosis. We sought to confirm and explore the role of SIRT2 in necroptosis and tested four different sources of the SIRT2 inhibitor AGK2, three independent short interfering RNAs (siRNAs) against Sirt2, and cells from two independently generated Sirt2 2/2 mouse strains; however, we were unable to show that inhibiting or depleting SIRT2 protected cells from necroptosis. Furthermore, Sirt2 2/2 mice succumbed to tumour-necrosis factor (TNF)-induced systemic inflammatory response syndrome (SIRS) more rapidly than wildtype mice, whereas Ripk3 2/2 mice were resistant. Our results therefore question the importance of SIRT2 in the necroptosis cell death pathway.
There are seven mammalian sirtuins, and work has focused on SIRT1, the closest homologue to the founding member of the sirtuin family, Saccharomyces cerevisiae Sir2. Mammalian SIRT2 has been reported to regulate cellular metabolism, division and differentiation 1, 2 . A recent study suggested an additional role, namely that SIRT2 is required for programmed necrosis, otherwise known as necroptosis 3 . Using co-immunoprecipitation followed by mass-spectrometric analysis, Narayan et al. 3 found that SIRT2 interacted with RIPK3 (called RIP3 in ref. 3) , a kinase that is essential for TNF-induced necroptosis [4] [5] [6] . Using a SIRT2 inhibitor, AGK2 (ref. 7) , they observed that SIRT2 deacetylase activity was required for formation of the RIPK1-RIPK3 (RIPK1 is called RIP1 in ref.
3) complex in response to the necroptosis-inducing stimulus of TNF, plus the caspase inhibitor z-VAD-fmk, and the translation inhibitor cycloheximide. Narayan et al. 3 proposed that SIRT2-mediated deacetylation of a lysine residue near the RIPK3-interacting RHIM motif of RIPK1 was required for RIPK1-RIPK3 association and necroptosis induction. Consistent with this hypothesis, they showed that knockdown, knockout or inhibition of Sirt2/SIRT2 prevented TNF-induced necroptosis in vitro 3 . The necroptotic cell death pathway has attracted interest because inhibiting it, particularly in conjunction with blocking apoptosis, is thought to have the potential to ameliorate diverse inflammatory and possibly also degenerative diseases [8] [9] [10] [11] . Notably, Narayan et al. 3 reported that genetic ablation or pharmacological blockade of Sirt2/SIRT2 afforded mice significant protection from injury caused by cardiac ischaemia reperfusion.
The therapeutic potential of these findings prompted us to confirm and explore the role of SIRT2 in necroptosis. We tested the ability of four different sources of the SIRT2 inhibitor, AGK2, at a broad range of concentrations, to inhibit necroptosis triggered by TNF, Smac mimetic and the caspase inhibitor Q-VD-OPh (TSQ), TNF plus z-VAD-fmk (TZ) or TNF plus z-VAD-fmk and cycloheximide (TCZ). In contrast to the findings of ref. 3 , AGK2 failed to inhibit TNF-induced necroptosis in our experiments ( Fig. 1a and Appendix Fig. 1 ). As previously described 7 , AGK2 (Sigma) increased levels of acetylated tubulin in NIH 3T3 cells, validating its ability to inhibit SIRT2 at the doses used (Appendix Fig. 1 ). Narayan et al. 3 found that two independent short hairpin RNAs (shRNAs) used to knock down Sirt2 expression prevented TZ-induced necroptosis in L929 cells. In our experiments, three independent siRNAs, which reduced Sirt2 expression by greater than 80%, failed to inhibit TZ-induced necroptosis in L929 cells (Fig. 1b and Appendix Fig. 1 ). We also tested mouse embryonic fibroblasts (MEFs) and bone-marrow-derived macrophages (BMDMs) from two independently generated Sirt2 knockout mouse strains (Appendix Fig. 1 ), but found neither cell type to be protected from TNF-induced necroptotic death (Fig. 1c, d) .
Finally, Narayan et al. 3 observed that Sirt2-deficient mice were protected from cardiac ischaemia-reperfusion injury and concluded that transient inhibition of SIRT2 might provide protection from diseases involving necroptosis. Because RIPK3-deficient mice have not been tested for their ability to resist cardiac ischaemia-reperfusion injury, we tested the response of Sirt2 2/2 mice to a well-established RIPK3-dependent necroptotic insult: we injected wild-type, Ripk3 2/2 and Sirt2 2/2 mice with TNF and monitored their body temperature. As previously described 8 , the core body temperature of wild-type mice dropped rapidly after injection of 300 mg kg 21 of TNF, and some of these animals died within the indicated time frame. In contrast, Ripk3 2/2 mice maintained normal body temperature and all survived. Far from being protected against this necroptosis-inducing insult, Sirt2 2/2 mice were more sensitive than their wild-type counterparts, and all died within the indicated time frame (Fig. 1e and Appendix Fig. 1) .
These experiments, performed with SIRT2 inhibitors, Sirt2 knockdown cells, Sirt2 2/2 mice and cells from two independently derived Sirt2 2/2 mice, raise doubts about the claimed role for SIRT2 in necroptotic cell death.
METHODS
Data were generated by nine independent laboratories. We have endeavoured to provide key experimental information, and detailed experimental methods are available on request. AGK2 was sourced from TOCRIS Bioscience (3233), Sigma (A8231), Biovision and the Kazatsev laboratory 7 . Cell survival was measured using propidium iodide exclusion and flow cytometric analysis, Cell Titer Glo assay (Promega) and IncuCyte system counting of SYTOX-green-positive cells in real time. Sirt2 2/2 mice were provided by the Donmez and Auwerx laboratories 12, 13 . TNF was sourced from Peprotech or made in house. Published protocols for siRNA, BMDM maturation and SIRS experiments were followed 8, 14, 15 .
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